Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is small cell carcinoma of the ovary?
Small cell carcinoma of the ovary, hypercalcemic type — usually abbreviated SCCOHT — is an extremely rare but very aggressive ovarian cancer that strikes young women, with an average age in the early-to-mid twenties. 'Hypercalcemic type' refers to the high blood-calcium level seen in about two-thirds of patients, which can cause nausea, confusion, and kidney problems and usually resolves once the tumor is treated. The defining discovery is genetic: nearly all of these tumors are caused by inactivation of a single gene, SMARCA4 (which makes a protein called BRG1, part of the SWI/SNF complex that helps control which genes are switched on). Because the loss can be inherited, genetic counseling is recommended. Despite the name 'small cell,' it is biologically unrelated to small cell lung cancer. It is rare enough that no single standard of care exists, so treatment combines aggressive surgery, intensive multi-drug chemotherapy, and radiation, often at expert centers and on clinical trials.
The main types
Doctors group small cell carcinoma of the ovary by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Hypercalcemic type (SCCOHT) | By far the most common form; the SMARCA4-driven cancer of young women, often with high blood calcium. This is what 'small cell carcinoma of the ovary' usually means. |
| Pulmonary type | A separate, much rarer ovarian tumor that resembles small cell lung cancer and occurs in older women; a different disease that is staged and treated differently. |
| Germline vs. somatic SMARCA4 loss | Not a tumor subtype but an important distinction — whether the SMARCA4 change is inherited (germline, warranting family testing) or arose only in the tumor (somatic). |
Staging, in plain terms
Like other ovarian cancers, SCCOHT is staged with the FIGO system, which describes how far the tumor has spread: confined to the ovary, to the pelvis, to the abdomen, or beyond. Because this cancer is aggressive and often advanced when found, accurate staging guides how intensive treatment needs to be.
| Ovarian cancer FIGO staging | What it generally means |
|---|---|
| Stage I | Confined to one or both ovaries. The most favorable group, but still treated aggressively because the cancer behaves unpredictably. |
| Stage II | Spread to other pelvic structures such as the uterus or fallopian tubes. |
| Stage III | Spread to the lining of the abdomen or to lymph nodes — the most common stage at diagnosis. |
| Stage IV | Spread to distant organs such as the lungs or liver. Treated with the most intensive multimodal approaches. |
The standard of care
Small Cell Carcinoma of the Ovary is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery (cytoreduction)
Removing as much tumor as possible — often the affected ovary and, depending on spread and fertility wishes, more extensive surgery — is a key step, ideally leaving no visible disease.
Intensive chemotherapy
Aggressive multi-drug, platinum-based chemotherapy is the backbone. Some centers use very high-dose chemotherapy with stem-cell (bone-marrow) rescue, which has been linked to better outcomes in this disease.
Radiation therapy
Radiation to the pelvis or abdomen is often added to improve local control after surgery and chemotherapy, and to treat sites that can't be fully removed.
Targeted and immune therapy (emerging)
Because the tumors lack SMARCA4, they may respond to drugs that exploit that weakness — such as EZH2 inhibitors, CDK4/6 inhibitors, and immune checkpoint inhibitors — which are being studied and used in advanced or relapsed disease.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide and survive, while healthy cells repair themselves more effectively. In SCCOHT, radiation is used after surgery and chemotherapy to improve control in the pelvis and abdomen, where this aggressive cancer tends to recur, and to treat areas that surgery cannot reach. It is delivered as a series of short, painless daily sessions, uses no radioactive implants, and leaves no radioactivity in your body — so you remain safe to be around family and children throughout.
The main ways radiation is delivered for small cell carcinoma of the ovary:
Pelvic / whole-abdominal radiation
Carefully planned x-ray radiation treats the pelvis or, in selected cases, the whole abdomen to destroy microscopic cancer left after surgery and chemotherapy.
Intensity-modulated radiation therapy (IMRT)
Computer-shaped beams concentrate dose on at-risk areas while sparing the bowel, kidneys, and bladder to reduce side effects.
Stereotactic / palliative radiation
Focused, high-dose radiation can target individual metastases or relieve symptoms such as pain when the disease has spread.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
SMARCA4 loss defines the disease: Over 95% of SCCOHT tumors are driven by inactivating SMARCA4 (BRG1) mutations, which can be germline; this finding has unified diagnosis, prompted family genetic testing, and opened the door to targeted therapy.[1]
Clinical Cancer Research review (AACR, 2020); Frontiers in Oncology mini-review (2025)
Multimodal therapy and high-dose chemotherapy improve outcomes: Systematic reviews report that aggressive surgery plus intensive chemotherapy — sometimes with high-dose chemotherapy and stem-cell rescue — and radiation offer the best chance of long-term survival in this otherwise high-risk cancer.[2]
SCCOHT systematic review (PMC10417391, 2023)
Targeting the SMARCA4 weakness: Because the tumors lack SMARCA4, they are sensitive to EZH2 inhibitors, CDK4/6 inhibitors, and immune checkpoint blockade in laboratory and early clinical studies, pointing toward more effective, less toxic future treatment.[3]
Translational SCCOHT studies (2024–2025)
Common questions
Is this the same as small cell lung cancer? No. Despite sharing the words 'small cell,' SCCOHT is a completely different disease with a different cause (loss of the SMARCA4 gene) and a different treatment. The name only reflects how the cells look under the microscope.
Why am I being offered genetic testing? Because the SMARCA4 change that causes this cancer can be inherited. Genetic testing tells you whether the change is in all your cells (germline) — which has implications for your relatives and for monitoring — or only in the tumor. Either way, it can guide treatment choices.
Why is my blood calcium high, and is it dangerous? About two-thirds of patients have a high calcium level caused by a substance the tumor releases. It can make you feel nauseated or confused and needs prompt treatment, but it usually improves once the cancer is treated. Your team will manage it with fluids and medication.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- Clinical Cancer Research review (AACR, 2020); Frontiers in Oncology mini-review (2025) (no indexed identifier — see your care team) ↩
- SCCOHT systematic review (PMC10417391, 2023) (no indexed identifier — see your care team) ↩
- Translational SCCOHT studies (2024–2025) (no indexed identifier — see your care team) ↩